Efficacy of a standardized herbal formulation from Glycyrrhiza glabra L. as an adjuvant treatment in hospitalized patients with COVID-19: A Randomized Controlled trial

Combination of Chinese herbal medicine and conventional western medicine for coronavirus disease 2019: a systematic review and meta-analysis

“…In total of 19 outcomes were determined to be “some concerns” in the domain of missing outcome data, due to 4 studies failed to report the complete or near complete outcome data from all participants ( 46 , 47 , 53 , 54 ). Seventeen outcomes were classified as “high risk” in 8 studies, as missing data in the outcomes might depend on their true values ( 50 , 53 – 59 ).…”

“…A total of 23 studies reported conversion to severe cases. Six of them were assessed as “low risk” ( 50 , 58 , 59 , 67 , 83 , 84 ), 11 as “some concerns” ( 47 , 54 , 62 , 64 , 69 , 76 , 78 , 82 , 86 , 88 , 89 ), and 6 as “high risk” ( 46 , 52 , 53 , 55 , 57 , 65 ). A total of 2,862 participants involved in CHM plus CWM groups, and 2,791 in CWM group.…”

“…A total of 2,862 participants involved in CHM plus CWM groups, and 2,791 in CWM group. The disease severity in 4 studies changed from severe to critical ( 53 , 58 , 67 , 88 ), and in 16 studies from mild or moderate to severe or critical ( 46 , 47 , 52 , 54 , 55 , 59 , 62 , 64 , 65 , 69 , 76 , 82 – 84 , 86 , 89 ). Three studies provided no detailed definition of “rate of conversion to severe cases” ( 50 , 57 , 78 ).…”

“…The results of the meta-analysis on 11 studies reporting mortality indicated that the death rate in CHM plus CWM groups was lower than that in CWM groups (RR = 0.53, 95% CI [0.40, 0.70], I 2 = 0%, P < 0.0001, moderate certainty). Among 11 studies, 5 were classified into “low risk” ( 54 , 58 , 67 , 77 , 78 ), 3 into “some concerns” ( 61 , 62 , 76 ), and 3 into “high risk” ( 43 , 48 , 53 ). A total of 852 participants in CHM plus CWM groups and 810 in CWM groups.…”

“…Of the 36 studies reporting adverse reactions, 5 were assessed as “low risk” ( 50 , 53 , 67 , 83 , 84 ), 22 as “some concerns” ( 46 – 48 , 61 , 62 , 64 , 66 , 68 , 69 , 71 – 73 , 82 , 85 , 88 , 90 – 92 ), and 9 as “high risk” ( 43 , 45 , 49 , 51 , 52 , 54 , 56 , 59 , 65 ). The main adverse reactions contained diarrhea ( 45 – 48 , 50 , 51 , 56 , 59 , 62 , 64 , 65 , 67 , 72 , 75 , 78 , 82 , 84 , 89 , 91 ), vomiting ( 46 , 48 , 50 , 51 , 56 , 64 , 67 , 72 , 75 , 82 , 89 , 91 ), nausea ( 46 , 48 , 50 , 51 , 56 , 64 , 67 , 72 , 75 , 89 , 90 ), loss of appetite ( …”